A micro-lung chip with macrophages for targeted anti-fibrotic therapy

Area of Science:

• Pulmonary Medicine
• Immunology
• Biotechnology

Background:

• Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with unknown causes.
• Macrophages are immune cells involved in fibrosis but are challenging therapeutic targets due to their plasticity.
• Understanding macrophage roles is crucial for developing effective IPF treatments.

Purpose of the Study:

• To investigate the influence of macrophages on IPF development.
• To engineer a micro-lung chip for studying macrophage-mediated lung pathology.
• To identify potential therapeutic targets for macrophage-related IPF treatments.

Main Methods:

• Engineered a micro-lung chip with lung epithelium-interstitium tissue.
• Co-cultured the chip with macrophages to create a controlled immune environment.
• Utilized bleomycin (BLM) treatment to model inflammation and fibrosis stages.
• Performed transcriptome analysis to identify key signaling pathways.
• Administered a PI3K inhibitor (LY294002) to assess its effects.

Main Results:

• Macrophages exacerbated inflammation and fibrosis in the micro-lung chip model.
• PI3K-AKT pathway activation was linked to the transition from inflammation to fibrosis.
• PI3K inhibition suppressed fibrosis and M2 macrophage accumulation but worsened inflammation.
• Macrophages play a pivotal role in IPF progression at the tissue level.

Conclusions:

• The micro-lung chip is a valuable tool for studying IPF pathogenesis and macrophage roles.
• Targeting the PI3K-AKT pathway requires careful consideration due to dual effects on inflammation and fibrosis.
• Further research using this model can elucidate anti-fibrotic drug mechanisms and identify new therapeutic strategies for IPF.